Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer.
about
Clinical application of a 3D ultrasound-guided prostate biopsy systemRelationship between initial PSA density with future PSA kinetics and repeat biopsies in men with prostate cancer on active surveillanceSaudi oncology society and Saudi urology association combined clinical management guidelines for prostate cancerCurrent status of active surveillance in prostate cancerActive surveillance and focal therapy for low-intermediate risk prostate cancerPotential Utility of Novel Biomarkers in Active Surveillance of Low-Risk Prostate CancerActive surveillance for prostate cancer: when to recommend delayed interventionHistological outcomes after focal high-intensity focused ultrasound and cryotherapyTreatment options for localized prostate cancerPopulation screening for prostate cancer: an overview of available studies and meta-analysisCurrent clinical challenges in prostate cancerManagement of low (favourable)-risk prostate cancerCancer screening in the United States, 2015: a review of current American cancer society guidelines and current issues in cancer screeningActive surveillance as a practical strategy to differentiate lethal and non-lethal prostate cancer subtypesFocal therapy in prostate cancer: the current situationCan contemporary patients with biopsy Gleason score 3+4 be eligible for active surveillance?Elevated serum microRNA levels associate with absence of high-grade prostate cancer in a retrospective cohortLoss of tumor suppressor mir-203 mediates overexpression of LIM and SH3 Protein 1 (LASP1) in high-risk prostate cancer thereby increasing cell proliferation and migration.Research Needs for Understanding the Biology of Overdiagnosis in Cancer Screening.Comparison of MR/ultrasound fusion-guided biopsy with ultrasound-guided biopsy for the diagnosis of prostate cancer.Using routinely collected data to stratify prostate cancer patients into phases of care in the United Kingdom: implications for resource allocation and the cancer survivorship programme.Costs of conservative management of early-stage prostate cancer compared to radical prostatectomy-a claims data analysisLow serum total testosterone level as a predictor of upstaging and upgrading in low-risk prostate cancer patients meeting the inclusion criteria for active surveillance.NF-κB gene signature predicts prostate cancer progression.Prostate Cancer Prevention Trial risk calculator 2.0 for the prediction of low- vs high-grade prostate cancer.Prostate volume and biopsy tumor length are significant predictors for classical and redefined insignificant cancer on prostatectomy specimens in Japanese men with favorable pathologic features on biopsyImage guidance for focal therapy of prostate cancer.Predicting 15-year prostate cancer specific mortality after radical prostatectomy.Laser ablation as focal therapy for prostate cancer.Epigenetic Signature: A New Player as Predictor of Clinically Significant Prostate Cancer (PCa) in Patients on Active Surveillance (AS)Active surveillance for low-risk prostate cancer compared with immediate treatment: a Canadian cost comparison.Cost consideration in utilization of multiparametric magnetic resonance imaging in prostate cancer.Evolution from active surveillance to focal therapy in the management of prostate cancer.Targeted prostate biopsy in select men for active surveillance: do the Epstein criteria still apply?Pathological stage distribution in patients treated with radical prostatectomy reflecting the need for protocol-based active surveillance: results from a contemporary European patient cohort.Early experience in MRI-guided therapies of prostate cancer: HIFU, laser and photodynamic treatment.Updated counselling for the patient with prostate cancer.Active surveillance for prostate cancer: patient selection and management.Androgen deprivation therapy for prostate cancer-review of indications in 2010Molecular profiling of indolent human prostate cancer: tackling technical challenges to achieve high-fidelity genome-wide data.
P2860
Q24608010-6C1F54DE-B49A-43EA-AD74-B6F4CBF09152Q24627957-F9287131-F9B9-48B4-B5D6-A55D43F5DE87Q26747782-9B8F7769-C10D-405C-BB4B-C3D8F0E2B861Q26766307-DBC31783-3D85-4FB4-BB17-AEA0EFF36714Q26773641-727949E0-61D0-4778-B91C-81A7F729AACBQ26784517-1B95003B-99AF-4D1D-B804-CC6090C682B7Q26801195-96C684B9-4DAC-4974-956D-C161DFDEB4E5Q26820469-B1584F8E-2F38-4097-8724-1260A51B68D8Q26825653-FA370BE6-AB06-48DA-A93B-89CD708F3A20Q26829319-769BDAEA-0212-4D2C-A7FB-2421DCD76FD5Q26866036-E41C1709-F6AB-4014-B193-87DD2C97F23AQ26996501-FB027994-29E5-4F04-B78B-B8CE27CDCDB7Q27001043-79BA433A-CE46-4770-9529-E33B78C1C0BDQ27010695-1D31C8C7-720B-44FB-98D4-893A2F05BD63Q28242346-590BAB97-A2E8-494B-AE5B-28439DB12380Q28543448-EC461763-13AD-4C9E-85E0-6FFC50B9BD39Q28546311-37A5D210-2FE4-48E9-A9D4-0EC5F2CA7D2FQ30009388-B8C348C6-BEFB-4AA5-8730-82BE7CD9567EQ30252065-50F0496E-EF37-4018-9E12-ED52160114B8Q30664726-69C60993-C43B-4058-8468-366E27F3B713Q30912685-DE0C3FC1-FA23-4898-BC33-023205ECF6CAQ31143305-8B49E6D9-E6B4-4961-A10E-CB24DDD3295FQ33566981-4C74FEC4-AE2B-4CDF-81D4-591FCEC63E2BQ33624908-181BCDFD-8193-4C7A-B764-113ECE4AD7F8Q33672510-4E4380E6-4F87-4458-8995-F883AEE76AADQ33717988-28CFA5EC-54DF-4B6E-8B4D-095233C52D58Q33724312-D6904F32-23EB-4F15-8A54-D8B72D6C54DAQ33759725-4BB30C15-8130-4953-B5EC-C086259C7C52Q33807516-7835A75B-62A3-42E0-ADD9-C5BF7508390BQ33838513-E7662363-FCC1-40E1-8875-2C3F11C57B0EQ33855285-D429269A-BA18-4572-B493-9FEA21A78B06Q33890201-CA739310-65FB-41D5-8836-E275CB8E1934Q33933490-5E11800A-7727-4041-BA0E-D8F064997382Q34032598-9F7C5CCC-A2B2-4FEA-8122-177B001C41AFQ34076949-3CE3D0C4-4EB1-41D2-AE34-A967AE4D55F9Q34107347-7F1C9DF1-FB52-4B89-A325-7D1A9F81C8AAQ34108870-42DA420F-29DA-4699-BB34-1D7081ED47A4Q34111584-5E59F713-5091-47D5-9B53-ACE08CF93C30Q34111603-7B6A9558-B247-4A68-9C39-BCA217332730Q34151167-7818B8D2-4A37-4C09-962D-324B6AA19C46
P2860
Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh-hant
name
Clinical results of long-term ...... ith localized prostate cancer.
@en
Clinical results of long-term ...... ith localized prostate cancer.
@nl
type
label
Clinical results of long-term ...... ith localized prostate cancer.
@en
Clinical results of long-term ...... ith localized prostate cancer.
@nl
prefLabel
Clinical results of long-term ...... ith localized prostate cancer.
@en
Clinical results of long-term ...... ith localized prostate cancer.
@nl
P2093
P356
P1476
Clinical results of long-term ...... ith localized prostate cancer.
@en
P2093
Alexandre Mamedov
Andrew Loblaw
Liying Zhang
Robert Nam
P304
P356
10.1200/JCO.2009.24.2180
P407
P577
2009-11-16T00:00:00Z